NFA
TVTX icon

Nationwide Fund Advisors’s Travere Therapeutics TVTX Stock Holding History

Nationwide Fund Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-57,776
Closed -$1.44M – 1956
2017
Q3 		$1.44M Sell
57,776
-1,648
-3% -$36.3K 0.01% 1600
2017
Q2 		$1.15M Buy
59,424
+7,583
+15% +$138K ﹤0.01% 1709
2017
Q1 		$957K Buy
51,841
+29,290
+130% +$573K ﹤0.01% 1771
2016
Q4 		$427K Sell
22,551
-793
-3% -$16.2K ﹤0.01% 2257
2016
Q3 		$522K Hold
23,344
– – ﹤0.01% 2162
2016
Q2 		$416K Buy
23,344
+862
+4% +$14K ﹤0.01% 2242
2016
Q1 		$307K Sell
22,482
-675
-3% -$10.2K ﹤0.01% 2324
2015
Q4 		$447K Buy
23,157
+505
+2% +$10.1K ﹤0.01% 2164
2015
Q3 		$459K Hold
22,652
– – ﹤0.01% 2164
2015
Q2 		$751K Buy
22,652
+5,369
+31% +$147K ﹤0.01% 2029
2015
Q1 		$414K Buy
17,283
+1,388
+9% +$21.2K ﹤0.01% 2331
2014
Q4 		$195K Sell
15,895
-492
-3% -$5.09K ﹤0.01% 2650
2014
Q3 		$148K Buy
16,387
+2
+0% +$24 ﹤0.01% 2840
2014
Q2 		$192K Buy
16,385
+10,554
+181% +$143K ﹤0.01% 2772
2014
Q1 		$124K Buy
+5,831
New +$89.7K ﹤0.01% 2674

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nationwide Fund Advisors's TVTX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Travere Therapeutics (TVTX) in Q4 2017, closing a stake of 57,776 shares — an estimated $1.44M sold.

Nationwide Fund Advisors first reported a position in TVTX in Q1 2014 and held it in 15 quarters. The position peaked at $1.44M in Q3 2017. 120 funds tracked by Wall St. Rank hold TVTX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Travere Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 57,776 Travere Therapeutics shares in Q4 2017, an estimated $1.44M.
  • Nationwide Fund Advisors first reported a position in Travere Therapeutics in Q1 2014 and held it in 15 quarters.
  • Nationwide Fund Advisors's Travere Therapeutics position peaked at $1.44M in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.